Holzer Holzer & Fistel, LLC is investigating whether Peregrine Pharmaceuticals, Inc. (“Peregrine” or the “Company”) (NASDAQ: PPHM) and/or its officers or directors have violated the federal securities laws. The investigation focuses on whether a series of statements regarding the Company’s business, its prospects and its operations were materially false and misleading at the time they were made. On September 24, 2012, Peregrine stated that investors “should not rely on clinical data that the company disclosed on or before September 7, 2012 from its Phase II bavituximab trial in patients with second-line non-small cell lung cancer or any presentations or other documents related to this Phase II trial.” Peregrine stock’s price declined dramatically on the news. If you purchased Peregrine common stock between September 7, 2012 and September 24, 2012 and have questions concerning your legal rights, you are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel Jr., Esq. or Marshall P. Dees, Esq. via email at email@example.com, or firstname.lastname@example.org, or via toll-free telephone at (888) 508-6832. Holzer Holzer & Fistel, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.